Personalis, Inc.

NASDAQ:PSNL

Medical - Diagnostics & Research

Healthcare
$14.98 +3.44%

+$0.34 today

Market cap
$1.62B
Beta
2.28
P/E (TTM)
-11.0
EPS (TTM)
-$0.92
52W Low $3.84High $12.53

Volume 1.47M

Average 2.31M

PSNL Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Personalis, Inc.NASDAQ: PSNL

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $14.54M rose 15.0% year over year, ahead of the +6.9% change in trailing-twelve-month research & development. Sequentially, it rose 11.2% from the prior quarter. Over 3 fiscal years it compounded at -8.2% a year.

Context

  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +15.0% holds above the trailing-twelve-month pace of +6.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$14.54M+11.2% QoQ
Last fiscal yearDec 2025
$50.26M+2.8% YoY
LTMMar 2026
$52.16M+6.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+15.0%——
1 year+2.8%——
3-year CAGR-8.2%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
50.26M USD
Year-over-year change
+2.8%
4-year CAGR
+0.5%

Research & Development vs competitors

How PSNL compares with its peers on the latest reported figures

  • PSNL's LTM Mar 2026 research & development of $52.16M is the 9th highest of the 10 companies compared; the peer median is $93.37M.
  • Its year-over-year change of +6.9% is the 8th highest of 10, against a peer median of +11.9%.
  • Research & development amounts to 80.9% of revenue for PSNL, versus a peer median of 17.4%.
PSNL Competitors Peer median
Research & Development for PSNL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTRANatera, Inc.LTM Jun 2026$787.38M +56.9%+25.4%29.1%
GHGuardant Health, Inc.LTM Sep 2026$386.67M +7.6%-0.9%30.2%
GRALGRAIL, Inc.LTM Jun 2026$190.99M -15.8%-15.9%115.6%
MYGNMyriad Genetics, Inc.LTM Mar 2026$106.4M -7.7%+7.7%12.8%
VCYTVeracyte, Inc.LTM Jun 2026$93.37M +31.8%+20.4%16.6%
WGSGeneDx Holdings Corp.LTM Jun 2026$83.32M +64.3%-5.8%18.3%
BLLNBillionToOne, Inc.LTM Jun 2026$59.21M +38.6%—14.9%
FLGTFulgent Genetics, Inc.LTM Mar 2026$55.69M +11.9%+23.1%17.4%
PSNLPersonalis, Inc.LTM Mar 2026$52.16M +6.9%-8.2%80.9%
NEONeoGenomics, Inc.LTM Jun 2026$38.17M +9.5%+6.9%5.0%
Peer median (excluding PSNL) $93.37M+11.9%+7.3%17.4%

Competitors are the stored peer set for PSNL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue85.49M65.05M73.48M84.61M0
Cost of Revenue53.84M51.7M55.27M57.79M53.87M
Gross Profit31.66M13.35M18.21M26.83M(53.87M)
Gross Margin37.0%20.5%24.8%31.7%—
Research & Development49.31M64.91M64.78M48.91M50.26M
Selling, General & Admin47.7M63.97M49.73M46.19M53.57M
Operating Expenses97.01M128.88M128.14M95.09M34.19M
Depreciation & Amortization6.01M8.43M11.3M10.94M10.05M
EBITDA(59.01M)(104.64M)(96.81M)(70.3M)(71M)
EBITDA Margin-69.0%-160.9%-131.7%-83.1%—
Operating Income(65.35M)(115.53M)(109.94M)(68.27M)(88.06M)
Operating Margin-76.4%-177.6%-149.6%-80.7%—
Interest Income367K2.4M5.9M5.51M7.16M
Interest Expense184K201K110K24K205K
Other Income / Expenses141K2.26M1.72M(13M)6.81M
Income Before Tax(65.21M)(113.28M)(108.21M)(81.27M)(81.25M)
Pre-Tax Margin-76.3%-174.1%-147.3%-96.0%—
Income Tax Expense14K40K83K18K21K
Net Income(65.23M)(113.32M)(108.3M)(81.28M)(81.27M)
Net Margin-76.3%-174.2%-147.4%-96.1%—
EPS (Basic)(1.49)(2.48)(2.25)(1.37)(0.91)
EPS (Diluted)(1.49)(2.48)(2.25)(1.37)(0.91)
Weighted Avg Shares43.89M45.7M48.18M59.25M89.24M
Weighted Avg Shares (Diluted)43.89M45.7M48.18M59.25M89.24M

Personalis, Inc.

NASDAQ:PSNL

Intrinsic Alpha fair value

Locked

Current Price

$14.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.